Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations

Clinical and Experimental Immunology

Volumn 161, Issue 3, 2010, Pages 527-535

  Patrias, L M ^a   Klaver, A C ^a   Coffey, M P ^a   Loeffler, D A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

ELISA; Intravenous immunoglobulin therapy (IVIG); Neuroimmunology; Parkinson's disease; Therapy immunotherapy

Indexed keywords

ALPHA SYNUCLEIN; ANTIBODY; BOVINE SERUM ALBUMIN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MONOMER; OLIGOMER; RECOMBINANT PROTEIN;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; DEMENTIA; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOTHERAPY; LEWY BODY; NEUROIMMUNOLOGY; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; WESTERN BLOTTING;

ALPHA-SYNUCLEIN; ANTIBODIES; BINDING, COMPETITIVE; BLOTTING, WESTERN; CAPRYLATES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; SOLUBILITY;

EID: 77955759369     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04214.x     Document Type: Article

References (46)

1. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001 276 : 2380 2386.
2. Uversky VN, Lee HJ, Li J, Fink AL, Lee SJ. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem 2001 276 : 43495 43498.
3. Miake H, Mizusawa H, Iwatsubo T, Hasegawa M. Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem 2002 277 : 19213 19219.
4. Uéda K, Fukushima H, Masliah E et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993 90 : 11282 11286.
5. Masliah E, Iwai A, Mallory M, Uéda K, Saitoh T. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am J Pathol 1996 148 : 201 210.
6. Culvenor JG, McLean CA, Cutt S et al. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol 1999 155 : 1173 1181.
7. Bayer TA, Jäkälä P, Hartmann T et al. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores. Neurosci Lett 1999 266 : 213 216.
8. Clayton DF, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 1999 58 : 120 129.
9. Sidhu A, Wersinger C, Vernier P. Alpha-synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett 2004 565 : 1 5.
10. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 1998 95 : 6469 6473.
11. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998 249 : 180 182.
12. Trojanowski JQ, Lee VM. 'Fatal attractions' of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. Ann NY Acad Sci 2000 924 : 62 7.
13. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007 27 : 3338 3346.
14. Gasser T.
15. Chartier-Harlin MC, Kachergus J, Roumier C et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004 364 : 1167 1169. (Pubitemid 28249037)
16. Krüger R, Kuhn W, Müller T et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998 18 : 106 108.
17. Lee SJ. Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J Mol Neurosci 2008 34 : 17 22.
18. El-Agnaf OM, Paleologou KE, Greer B et al. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J 2004 18 : 1315 1317.
19. Amer DA, Irvine GB, El-Agnaf OM. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. Exp Brain Res 2006 173 : 223 233.
20. Scheinfeld NS, Godwin JE. Intravenous immunoglobulin. Emedicine 2008. Last updated: 22 June 2010. Available at: http://emedicine.medscape.com/article/ 210367-overview (accessed 18 May 2010).
21. Dodel RC, Du Y, Depboylu C et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004 75 : 1472 1474.
22. Relkin NR, Szabo P, Adamiak B et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009 30 : 1728 1736.
23. Shankle WR, Hara J. Longitudinal measure of IVIG treatment effect in patients with Alzheimer's and Lewy body disease. Alzheimers Dement 2009 5 : P430.
24. Nanri K, Okita M, Takeguchi M et al. Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia. Intern Med 2009 48 : 783 790.
25. Papachroni KK, Ninkina N, Papapanagiotou A et al. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 2007 101 : 749 756.
26. Li Q, Gordon M, Cao C, Ugen KE, Morgan D. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci 2007 8 : 22.
27. Klaver AC, Finke JM, Digambaranath J, Balasubramaniam M, Loeffler DA. Antibody concentrations to Aβ1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated in intravenous immunoglobulin preparations. Int Immunopharmacol 2010 10 : 115 119.
28. Heidelberger M, Kendall FE. A quantitative theory of the precipitin reaction. III. The reaction between crystalline egg albumin and its homologous antibody. J Exp Med 1935 62 : 697 720.
29. Dunnett CW. Pairwise multiple comparisons in the unequal variance case. J Am Stat Assoc 1980 75 : 796 800.
30. Korhonen MP. On the performance of some multiple comparison procedures with unequal variances. Scand J Statist 1982 9 : 241 247.
31. Beck DA, Rossen RD, Cangir A, DuBois DB. Correlation of immune complexes in disseminated neuroblastoma with serum antibody to bovine serum albumin. Cancer Res 1983 43 : 879 885.
32. Karjalainen J, Saukkonen T, Savilahti E, Dosch HM. Disease-associated anti-bovine serum albumin antibodies in type 1 (insulin-dependent) diabetes mellitus are detected by particle concentration fluoroimmunoassay, and not by enzyme linked immunoassay. Diabetologia 1992 35 : 985 990.
33. Lamari F, Anastassiou ED, Tsegenidis T, Dimitracopoulos G, Karamanos NK. An enzyme immunoassay to determine the levels of specific antibodies toward bacterial surface antigens in human immunoglobulin preparations and blood serum. J Pharm Biomed Anal 1999 20 : 913 920.
34. Krause I, Wu R, Sherer Y, Patanik M, Peter JB, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations - a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 2002 12 : 133 139.
35. Khan S, Sims S, Raine D, Sewell WA. Both autoantibodies and pathogen-specific antibodies are present in immunoglobulin preparations and reflect characteristics of the donor population. J Am Acad Dermatol 2008 59 : 1089 1090.
36. Lejtenyi D, Mazer B. Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations. J Allergy Clin Immunol 2008 121 : 254 255.
37. Reipert BM, Stellamor MT, Poell M et al. Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin. Vox Sang 2008 94 : 334 341.
38. Klaver AC, Patrias LM, Coffey MP, Finke JM, Loeffler DA. Measurement of anti-Aβ1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding. J Neurosci Methods 2010 187 : 263 269. Epub 25 January 2010.
39. Beyer K, Ariza A. The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies. Curr Med Chem 2008 15 : 2748 2759.
40. Emadi S, Liu R, Yuan B et al. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 2004 43 : 2871 2878.
41. Iwai A, Masliah E, Yoshimoto M et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995 14 : 467 475.
42. El-Agnaf OM, Salem SA, Paleologou KE et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003 17 : 1945 1947.
43. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001 98 : 8850 8855.
44. Zhang W, Wang T, Pei Z et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005 19 : 533 542.
45. Klegeris A, Giasson BI, Zhang H, Maguire J, Pelech S, McGeer PL. Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J 2006 20 : 2000 2008.
46. Masliah E, Rockenstein E, Adame A et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005 46 : 857 868.